Curry M et al. Clinical Practice experience with pan genotypic therapies glecaprevir-pibrentasvir and sofosbuvir-velpatasvir in the TRIO. (Abstract THU-127),Cornberg M et al. Real-world safety, effectiveness, and patient-reported outcomes in patients with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: Data from the German Hepatitis C-Registry Network.
Minder long COVID bij gevaccineerde mensen met een donornier
mei 2024 | Niertransplantatie, Vaccinatie, Virale infecties